

# Steve Saviuk on Valeo Pharma's Redesca, an injectable anticoagulant drug that just commenced shipment in Canada

written by InvestorNews | May 7, 2021

In a recent InvestorIntel interview, Tracy Weslosky spoke with Steve Saviuk, CEO of [Valeo Pharma Inc.](#) (CSE: VPH | OTCQB: VPHIF) about the [commercial launch](#) of Valeo's low molecular weight heparin (LMWH) biosimilars – Redesca™ and Redesca HP™.

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), Steve went on to say that Valeo has commenced shipments across Canada of Redesca™ and Redesca HP™ which are now [covered under](#) the Ontario Public Drug Benefit Program effective April 30, 2021. With Ontario representing 37% of the Canadian market for LMWHs, Steve explained the importance of listing of Redesca on the Ontario public formulary. He also spoke on the competitive advantages of Redesca which is an injectable anticoagulant drug with more than 8 years of proven in-market safety internationally and more than 150 million patient days treated in Europe alone.

To watch the full interview, [click here](#)

## About Valeo Pharma

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory diseases, Neurodegenerative Diseases, Oncology and Hospital Specialty

Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization.

To know more about Valeo Pharma Inc., [click here](#)

**Disclaimer:** Valeo Pharma Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the

Company's profile on [www.Sedar.com](http://www.Sedar.com) and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please email [info@investorintel.com](mailto:info@investorintel.com).